Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Key facts

Sponsor

University of Washington

Principal Investigator

James S Andrews, MD

University of Washington

Intervention

Gamunex-C(drug)

Eligibility

18-120 years · All sexes

Timeline

2022 – 2022

Study locations (1)

• University of Washington, Seattle, Washington, United States

Collaborators

Grifols Biologicals, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Immune-mediated necrotizing myopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07103746
  Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT06599697
  The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
  University of Alabama at Birmingham

See all trials for Immune-mediated necrotizing myopathy →